Annovis Bio, Inc.
ANVS
$2.60
-$0.10-3.70%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.83% | 12.92% | 65.57% | 32.05% | -40.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.55% | -35.50% | -70.48% | -20.46% | -21.66% |
| Operating Income | 19.55% | 35.50% | 70.48% | 20.46% | 21.66% |
| Income Before Tax | -418.99% | 73.60% | 14.12% | 47.36% | 89.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -418.99% | 73.60% | 14.12% | 47.36% | 89.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -418.99% | 73.60% | 14.12% | 47.36% | 89.04% |
| EBIT | 19.55% | 35.50% | 70.48% | 20.46% | 21.66% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -216.43% | 81.01% | 40.36% | 58.33% | 91.55% |
| Normalized Basic EPS | -216.08% | 81.01% | 40.36% | 58.33% | 91.54% |
| EPS Diluted | 55.39% | 78.65% | 40.36% | 58.50% | 39.50% |
| Normalized Diluted EPS | -222.24% | 81.01% | 40.36% | 58.33% | 91.70% |
| Average Basic Shares Outstanding | 64.06% | 38.99% | 43.98% | 26.33% | 29.65% |
| Average Diluted Shares Outstanding | 61.03% | 38.99% | 43.98% | 26.33% | 32.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |